Thermo Fisher Scientific (TMO) has been under pressure with near-term EPS challenges, but maintains a strong foothold in innovation according to Q2 2025 earnings overview. The company has recently acquired Sanofi's New Jersey manufacturing site, expanding its strategic partnership for additional U.S drug product manufacturing. TMO, predicted by analysts to have a possible decline in earnings, has been trading down due to concerns over spending cuts. Nevertheless, the company continues to attract investment attention with positive market ratings, despite battling policy storms. An agreement to manufacture Adial Pharmaceuticals' ADO4 along with the unveiling of next-day genomic profiling with Oncomine Assay Plus, both underline the company's emphasis on innovation. Thermo Fisher is currently exploring a $4 billion diagnostics sale, and its Oncomine Dx Express Test has received FDA approval. Sanctions like the $94.5 million DoD contract for US Navy Dosimetry Systems and Scotiabank upgrade to 'Outperform' status indicate a strong market position. Investors are encouraged to keep an eye on the company as the fundamentals remain robust despite present stock performance issues.
Thermo Fisher Scientific TMO News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sat, 19 Jul 2025 21:46:21 GMT -
Rating 2
- Innovation 8
- Information 7
- Rumor -5
